{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:59Z","timestamp":1786119359936,"version":"build-2736575974"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,8,24]]},"DOI":"10.1097\/qad.0b013e32832e0599","type":"journal-article","created":{"date-parts":[[2009,8,13]],"date-time":"2009-08-13T15:49:22Z","timestamp":1250178562000},"page":"1631-1640","source":"Crossref","is-referenced-by-count":6,"title":["Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor"],"prefix":"10.1097","volume":"23","author":[{"given":"Sarah K","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena E","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana M","family":"Coman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda C","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changxing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben M","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W","family":"Sleasman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen M","family":"Goodenow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-2-20210130","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1128\/JVI.80.7.3617-3623.2006","article-title":"Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1","volume":"80","author":"Martinez-Picado","year":"2006","journal-title":"J Virol"},{"key":"R3-2-20210130","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1128\/JVI.70.6.3763-3769.1996","article-title":"Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors","volume":"70","author":"Doyon","year":"1996","journal-title":"J Virol"},{"key":"R4-2-20210130","doi-asserted-by":"crossref","first-page":"7632","DOI":"10.1128\/JVI.72.9.7632-7637.1998","article-title":"Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients","volume":"72","author":"Mammano","year":"1998","journal-title":"J Virol"},{"key":"R5-2-20210130","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1128\/JVI.71.9.6662-6670.1997","article-title":"Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites","volume":"71","author":"Zhang","year":"1997","journal-title":"J Virol"},{"key":"R6-2-20210130","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1006\/viro.2001.1184","article-title":"Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease","volume":"292","author":"Goodenow","year":"2002","journal-title":"Virology"},{"key":"R7-2-20210130","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1089\/088922203769232575","article-title":"Polymorphisms in p1-p6\/p6* of HIV type 1 can delay protease autoprocessing and increase drug susceptibility","volume":"19","author":"Whitehurst","year":"2003","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R8-2-20210130","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.virol.2008.05.029","article-title":"Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)\/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response","volume":"378","author":"Ho","year":"2008","journal-title":"Virology"},{"key":"R9-2-20210130","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1371\/journal.pmed.0040036","article-title":"A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism","volume":"4","author":"Nijhuis","year":"2007","journal-title":"PLoS Med"},{"key":"R10-2-20210130","doi-asserted-by":"crossref","first-page":"7398","DOI":"10.1128\/JVI.76.15.7398-7406.2002","article-title":"Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro","volume":"76","author":"Maguire","year":"2002","journal-title":"J Virol"},{"key":"R11-2-20210130","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/jlb.62.1.138","article-title":"Inhibition of replication of HIV in primary monocyte\/macrophages by different antiviral drugs and comparative efficacy in lymphocytes","volume":"62","author":"Aquaro","year":"1997","journal-title":"J Leukoc Biol"},{"key":"R12-2-20210130","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0166-3542(02)00052-9","article-title":"Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir","volume":"55","author":"Aquaro","year":"2002","journal-title":"Antivir Res"},{"key":"R13-2-20210130","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1097\/00002030-200012220-00016","article-title":"Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages)","volume":"14","author":"Briggs","year":"2000","journal-title":"AIDS"},{"key":"R14-2-20210130","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1126\/science.1905842","article-title":"Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1","volume":"253","author":"Hwang","year":"1991","journal-title":"Science"},{"key":"R15-2-20210130","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1189\/jlb.0306148","article-title":"HIV-1 coreceptor preference is distinct from target cell tropism: a dual-parameter nomenclature to define viral phenotypes","volume":"80","author":"Goodenow","year":"2006","journal-title":"J Leukoc Biol"},{"key":"R16-2-20210130","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/00002030-200403050-00001","article-title":"Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy","volume":"18","author":"Brumme","year":"2004","journal-title":"AIDS"},{"key":"R17-2-20210130","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00002030-200401230-00014","article-title":"Virological phenotype switches under salvage therapy with lopinavir-ritonavir in heavily pretreated HIV-1 vertically infected children","volume":"18","author":"Galan","year":"2004","journal-title":"AIDS"},{"key":"R18-2-20210130","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1097\/00002030-200304110-00005","article-title":"Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations","volume":"17","author":"Skrabal","year":"2003","journal-title":"AIDS"},{"key":"R19-2-20210130","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1086\/318538","article-title":"Human immunodeficiency virus type 1 protease genotype predicts immune and viral responses to combination therapy with protease inhibitors (PIs) in PI-naive patients","volume":"183","author":"Perez","year":"2001","journal-title":"J Infect Dis"},{"issue":"RR\u20137","key":"R20-2-20210130","first-page":"1","article-title":"Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV","volume":"51","author":"Dybul","year":"2002","journal-title":"MMWR Recomm Rep"},{"issue":"1","key":"R21-2-20210130","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1542\/peds.102.1.101","article-title":"A phase I\/II study of the protease inhibitor indinavir in children with HIV infection","volume":"102","author":"Mueller","year":"1998","journal-title":"Pediatrics"},{"issue":"3","key":"R22-2-20210130","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1542\/peds.101.3.335","article-title":"A phase I\/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection","volume":"101","author":"Mueller","year":"1998","journal-title":"Pediatrics"},{"key":"R23-2-20210130","doi-asserted-by":"crossref","first-page":"e604","DOI":"10.1542\/peds.2004-0274","article-title":"Two-year clinical and immune outcomes in human immunodeficiency virus-infected children who reconstitute CD4 T cells without control of viral replication after combination antiretroviral therapy","volume":"114","author":"Ghaffari","year":"2004","journal-title":"Pediatrics"},{"key":"R24-2-20210130","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12026-007-0031-1","article-title":"Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children","volume":"40","author":"Rodriguez","year":"2008","journal-title":"Immunol Res"},{"key":"R25-2-20210130","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1006\/viro.1996.0266","article-title":"Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag\/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1","volume":"219","author":"Barrie","year":"1996","journal-title":"Virology"},{"key":"R26-2-20210130","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1089\/088922202753519133","article-title":"Increased replication of nonsyncytium-inducing HIV type 1 isolates in monocyte-derived macrophages is linked to advanced disease in infected children","volume":"18","author":"Tuttle","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R27-2-20210130","first-page":"62","article-title":"Update of the Drug Resistance Mutations in HIV-1: Spring 2008","volume":"16","author":"Johnson","year":"2008","journal-title":"Top HIV Med"},{"key":"R29-2-20210130","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S0042-6822(03)00484-7","article-title":"Covariation of amino acid positions in HIV-1 protease","volume":"314","author":"Hoffman","year":"2003","journal-title":"Virology"},{"key":"R30-2-20210130","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1089\/aid.1996.12.1401","article-title":"Covariability of V3 loop amino acids","volume":"12","author":"Bickel","year":"1996","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R31-2-20210130","doi-asserted-by":"crossref","first-page":"13376","DOI":"10.1128\/JVI.77.24.13376-13388.2003","article-title":"Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences","volume":"77","author":"Jensen","year":"2003","journal-title":"J Virol"},{"key":"R32-2-20210130","doi-asserted-by":"crossref","first-page":"5623","DOI":"10.1128\/JVI.67.9.5623-5634.1993","article-title":"V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability","volume":"67","author":"Milich","year":"1993","journal-title":"J Virol"},{"key":"R33-2-20210130","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1006\/viro.2001.1087","article-title":"Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks","volume":"288","author":"Resch","year":"2001","journal-title":"Virology"},{"key":"R34-2-20210130","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1089\/08892220050116970","article-title":"Polymorphism of HIV type 1 gag p7\/p1 and p1\/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors","volume":"16","author":"Bally","year":"2000","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R35-2-20210130","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-1-4615-5373-1_7","article-title":"A comparison of gag-pol precursor cleavage in naturally arising HIV variants","volume":"436","author":"Bloom","year":"1998","journal-title":"Adv Exp Med Biol"},{"key":"R36-2-20210130","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1089\/088922299311420","article-title":"Associations between amino acids in the evolution of HIV type 1 protease sequences under indinavir therapy","volume":"15","author":"Brown","year":"1999","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R37-2-20210130","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/00002030-200103090-00013","article-title":"Mutations in HIV-1 gag cleavage sites and their association with protease mutations","volume":"15","author":"Koch","year":"2001","journal-title":"AIDS"},{"key":"R38-2-20210130","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1128\/JVI.77.8.4836-4847.2003","article-title":"Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments","volume":"77","author":"Wu","year":"2003","journal-title":"J Virol"},{"key":"R39-2-20210130","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1128\/JCM.37.12.4099-4106.1999","article-title":"Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences","volume":"37","author":"Yahi","year":"1999","journal-title":"J Clin Microbiol"},{"key":"R40-2-20210130","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1086\/315334","article-title":"Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection","volume":"181","author":"Deeks","year":"2000","journal-title":"J Infect Dis"},{"key":"R41-2-20210130","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1097\/00002030-199912240-00005","article-title":"Immunologic and virologic responses to HAART in severely immunocompromised HIV-1-infected children","volume":"13","author":"Essajee","year":"1999","journal-title":"AIDS"},{"key":"R42-2-20210130","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0022-3476(99)70247-7","article-title":"Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages","volume":"134","author":"Sleasman","year":"1999","journal-title":"J Pediatr"},{"key":"R44-2-20210130","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1177\/135965350601100512","article-title":"Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG","volume":"11","author":"Abecasis","year":"2006","journal-title":"Antivir Ther"},{"key":"R45-2-20210130","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jcv.2004.03.015","article-title":"Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes","volume":"31","author":"Holguin","year":"2004","journal-title":"J Clin Virol"},{"key":"R46-2-20210130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jcv.2006.01.012","article-title":"Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients","volume":"36","author":"Vergne","year":"2006","journal-title":"J Clin Virol"},{"key":"R47-2-20210130","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1021\/bi7018332","article-title":"The contribution of naturally occurring polymorphisms in altering the biochemical and structural characteristics of HIV-1 subtype C protease","volume":"47","author":"Coman","year":"2008","journal-title":"Biochemistry"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002030-200908240-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:08:11Z","timestamp":1786039691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002030-200908240-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,24]]},"references-count":44,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e32832e0599","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8,24]]}}}